Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

The introduction of a revolutionary drug, Lenacapavir, is poised to alter the landscape of healthcare across sub-Saharan ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.Presented ...

The WHO has approved the use of a new drug to prevent HIV. The drug is called Lenacapavir, and what makes it unique is that ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...